Nektar Therapeutics (NKTR) Q3 2026 earnings review
Nektar speeds up its drug trials, while legal costs rise
Nektar Therapeutics, a biotechnology group developing immune-system drugs, started its final late-stage eczema trial while legal bills pushed overhead higher. Operating losses widened by 83% to $58 million as clinical trial spending climbed, while cash and investments dipped to $953 million. Chief executive Howard Robin moved the start of the late-stage hair-loss study forward to December, and quarterly cash use of $71 million stayed well below what the prior year-end plan pointed to by our math.
| Cash and marketable securities | $952.9M down $70.5M from last quarter |
|---|---|
| Research and development expense | $44.1M +62% from a year ago |
| General and administrative expense | $24.6M +53% from a year ago on legal bills |
| Alopecia Phase 3 trial start plan | Pulled forward December 2026 vs early 2027 prior target |
⚖️ Verdict: 🟢 Bullish
The story got better because Nektar launched all three registrational eczema studies and pulled its hair-loss trial into 2026 while preserving its cash buffer. Six-month off-treatment data also showed that hair regrowth held up after patients stopped injections, supporting less frequent maintenance dosing. One caution: lower third-quarter research spending says clinical bills are ramping up more slowly than the annual budget implied, while a 53% jump in overhead from legal costs threatens the full-year administrative budget.
The question now is whether Nektar's $953 million cash pile can fund both the eczema and hair-loss programmes past the summer 2028 data readouts without selling more stock. One view is that slower trial billing and high interest income keep the balance sheet comfortable; the other is that doubling research costs in 2027 and ongoing litigation will trigger more share sales. Fourth-quarter cash and research spending will tell.
🐂 Bull Case
All Three Eczema Studies Are Now Enrolling
"This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development," chief executive Howard Robin said. Rezpegaldesleukin is an experimental drug designed to calm an overactive immune system by boosting regulatory T cells. The biotechnology company wants to prove the drug can treat several chronic inflammatory conditions at once.
In October, Nektar started ZENITH AD-3, the third and final late-stage study for moderate-to-severe eczema. This study tests patients with "prior systemic biologic and/or JAK inhibitor treatment experience" in order "to support a broad label". Robin also said that "our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned".
Starting the hair-loss study in December pulls the timeline forward from early 2027. Collaborators at Mount Sinai also presented data from 100 eczema patients showing blood markers improved by week two, which strengthens the scientific case for the drug across multiple immune pathways.
What to watch: the start of the fourth clinical study in a new disease before year-end, along with Type 1 diabetes data in 2027. Hitting those dates would show the company can run four late-stage studies at once without delay.
Hair Regrowth Held Up After Stopping Treatment
Nektar is testing rezpegaldesleukin in severe alopecia areata, an autoimmune disease that causes patchy or complete hair loss. Because rival oral drugs often require daily pills to keep hair from falling out again, management wants to show that its immune-resetting approach lasts even after injections stop.
In October, researchers presented six-month off-treatment results from the mid-stage REZOLVE-AA study at a medical congress. Among the eight patients who reached the main hair-recovery threshold after a year of treatment, five kept that result six months after their last dose. In addition, the share of patients with almost complete hair coverage rose from 7% at week 52 to 19% six months later.
That continued regrowth matters because the study's original 36-week readout missed its main statistical goal before Nektar excluded four improperly enrolled patients. Showing that responses deepen and last off therapy gives the upcoming December Phase 3 trial a way to stand apart from daily pills, permitting dosing every four or twelve weeks.
What to watch: 52-week off-treatment results from the mid-stage eczema study in the first quarter of 2027. A similar lasting response in a much larger group of patients would confirm that infrequent maintenance dosing works across both diseases.
Cash Burn Stayed Below the Implied Pace
After raising more than $1 billion from stock sales over the past year, Nektar says its cash will fund operations into the third quarter of 2028. Two months ago, management forecast ending 2026 with $815 million to $840 million in cash and investments, which by our math pointed to $92 million to $104 million of cash use per quarter in the second half.
The company ended September with $952.9 million, down $70.5 million from June. Cash use stayed well below the implied pace because research and development spending reached $44.1 million, far short of the $68 million to $78 million quarterly average implied by the prior full-year R&D plan. Higher cash balances also generated $9.6 million in interest income, more than triple last year's level.
Beating the implied third-quarter burn rate means the company's spending budget was conservative or that clinical bills shifted into the fourth quarter. It does not reduce the total cost of the Phase 3 trials.
What to watch: year-end cash and marketable securities in the fourth-quarter report. Staying above $815 million without selling new stock under the $150 million equity programme would confirm that the 2028 cash buffer remains intact.
🐻 Bear Case
Legal Bills Lifted Overhead Costs by 53%
Nektar is fighting two major courtroom battles: a long-running lawsuit against former partner Eli Lilly, which had a jury trial scheduled for September 2026, and a shareholder class action filed in March over how the company presented its hair-loss trial data. Two months ago, management kept its full-year general and administrative budget at $60 million to $65 million.
In the third quarter, general and administrative expense jumped 52.9% from a year ago and 92.5% from the second quarter to $24.6 million. Nektar said the jump occurred "primarily due to an increase in legal expenses in the third quarter of 2026", yet the press release gave no update on the September Eli Lilly trial. Nine-month overhead reached $50.8 million.
That leaves only $11.7 million for the fourth quarter by our math at the middle of the prior full-year plan, less than half the third-quarter rate. The legal cost jump and the silence on the trial outcome undercut the view that overhead is declining as a share of spending.
What to watch: the legal-proceedings footnote in the third-quarter 10-Q filing. Any adverse ruling in the Eli Lilly trial or ongoing legal bills above $12 million in the fourth quarter would force Nektar to break its annual overhead budget.
Clinical Costs Widened the Operating Loss 83%
Running four global registrational studies without a big-pharma partner puts the entire trial bill on Nektar's income statement. While the headline net loss per share improved by 12.8% from a year ago to $1.63, that per-share decline happened only because stock offerings increased the average share count by 80.4% to 34.2 million.
- Loss from operations: $57.8 million, widened by 82.5% from $31.7 million a year ago
- Research and development: $44.1 million, up 61.9% from a year ago and 12.8% from last quarter
- General and administrative: $24.6 million, up 52.9% from a year ago
- Net loss: $55.7 million, widened by 56.7% from $35.5 million a year ago
The widening operating loss matters because the cost ramp is still in its early stages. By our math, hitting the middle of the prior $210 million to $230 million full-year R&D plan would require fourth-quarter research spending to reach $101.1 million, more than double the third-quarter level as patient enrolment accelerates.
What to watch: fourth-quarter R&D expense and any sales under the $150 million stock-issuance programme. If quarterly operating losses climb toward $90 million as trials fill up, Nektar may tap its stock facility and dilute shareholders again.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no resolving numbers or updates in the third-quarter press release because they depend on clinical readouts years away or detailed footnote disclosures.
- Single-drug dependency: nearly all company value rests on mid-2028 Phase 3 eczema data, with no fallback if efficacy falls short.
- Crowded 2029 market: rival oral and injectable drugs in eczema and alopecia will launch before Nektar files for approval in 2029.
- Injection-site reactions: about 70% of patients had skin reactions during induction; the release gave no new tolerability rates.
- Supplier and lease exposure: Gannet BioChem supplies key chemical reagents (recording a $0.6 million equity loss in Q3), and $73.9 million in San Francisco lease liabilities remain on the balance sheet.
💲 Other KPIs
Revenue fell 20.4% from a year ago and 7.4% from the second quarter. Excluding a $0.3 million license fee a year ago, non-cash royalty revenue dropped 18.3% by our math. Nektar sold its rights to future partner royalties years ago, so this accounting revenue shrinks as those drug agreements expire.
Other current assets rose 18.0% from $55.1 million in June and more than tripled from $20.5 million at the end of 2025. For Nektar, this line mainly tracks upfront cash prepayments to clinical-trial contractors before the work is recorded as research expense on the income statement.
Liabilities related to the sales of future royalties shrank 4.5% from $57.4 million in the second quarter and 13.3% from $63.2 million at year-end 2025. The balance goes down each quarter as partner royalties pay down the debt-accounted obligation, offset by $6.8 million of non-cash interest expense.
🔮 Guidance
Raised. Management pulled the start of the single registrational Phase 3 study in alopecia areata forward into December 2026 from its prior target of early 2027. Starting the hair-loss trial a quarter early accelerates patient enrollment and shifts startup payments into the fourth quarter of 2026.
Unchanged. Chief executive Howard Robin said the company remains "focused on advancing to our topline data readouts in the summer of 2028 with the first BLA filing in 2029". With all three eczema studies now active as of October, the timetable to the main clinical readout holds steady, though the press release gave no updated full-year 2026 financial ranges.
❓ Key Questions
What happened in the September Eli Lilly jury trial?
A jury trial against Eli Lilly was scheduled for September 8, 2026, and third-quarter overhead jumped 53% on legal bills. Yet the earnings release did not mention whether the trial took place, settled, or was delayed.
Does the $210–230 million R&D budget still hold?
Nine-month research spending is $118.9 million. Reaching the middle of the full-year plan set last quarter would require $101.1 million of R&D in the fourth quarter, more than double the third-quarter run rate.
Will full-year G&A breach the $60–65 million plan?
After third-quarter legal bills pushed nine-month general and administrative costs to $50.8 million, only $11.7 million remains to hit the middle of the prior annual forecast.
When will the fourth rezpegaldesleukin indication enter the clinic?
Last quarter management aimed to start a clinical study in a new disease before year-end 2026, and earlier plans targeted 2027 for the NKTR-0165 antibody. Neither appeared in the third-quarter release.